Lesson
Pregnancy Context and Medication Decisions
Medication use in pregnancy is a benefit and risk decision for two linked patients, not a search for a drug with zero uncertainty.
- Gestational age
- Maternal disease
- Baseline risk
- Shared decisions
- Preconception review
Confirm indication, exposure, gestational age, and clinical urgency
Include maternal relapse, fetal effects, and baseline pregnancy risk
State evidence, uncertainty, goals, and follow-up
Establish the timeline
Document the best obstetric estimate of gestational age, trimester, exposure dates, dose, route, duration, and indication. Gravidity and parity describe pregnancy history, but they do not replace the current gestational timeline.
Describe pregnancy history precisely
Gravidity counts pregnancies, including the current pregnancy, regardless of outcome or number of fetuses. In the U.S. convention used here, parity counts completed pregnancies delivered at 20 weeks or later, whether live birth or fetal death; a twin delivery counts once. For example, a patient currently eight weeks pregnant after one twin delivery at 36 weeks and one miscarriage at nine weeks is G3 P1. The number of living children is documented separately. In GTPAL notation, P means preterm births, not total parity.
Separate a positive test from location and viability
A positive hCG test supports pregnancy but does not establish a viable intrauterine pregnancy. A positive test with no pregnancy identified on ultrasound is a pregnancy of unknown location: possibilities include an early intrauterine pregnancy, a recent loss or an ectopic pregnancy. Clinical assessment, follow-up hCG and ultrasound guide the diagnosis. Severe abdominal pain, shoulder-tip pain or collapse requires urgent assessment; do not delay care while waiting for another routine hCG measurement.
Distinguish pregnancy clocks and term definitions
Gestational age is usually counted from the first day of the last menstrual period, about two weeks before conception in a typical cycle; use the best obstetric dating rather than assuming this offset is exact for everyone. Pregnancy averages about 40 gestational weeks. Birth before 37 weeks is preterm; 37 weeks through 38 weeks 6 days is early term, 39 weeks through 40 weeks 6 days is full term, 41 weeks through 41 weeks 6 days is late term, and 42 weeks onward is postterm.
Check prenatal nutrition
Pregnancy targets are total daily intakes, not automatic additional supplement doses: folate 600 mcg dietary folate equivalents (DFE), iron 27 mg, calcium 1,000 mg at ages 19 to 50 or 1,300 mg at ages 14 to 18, and vitamin D 15 mcg (600 IU). Review food and supplement contributions together. Prenatal products vary; a gummy may omit iron and calcium.
Keep folate units distinct
Folate DFE and folic-acid mass are not interchangeable. With food, 0.6 mcg folic acid supplies 1 mcg DFE. For example, 400 mcg folic acid with food supplies approximately 667 mcg DFE: 400 divided by 0.6. This nutrient conversion does not establish an individualized neural-tube-defect prevention regimen.
Start neural-tube-defect prevention before conception
CDC recommends 400 mcg folic acid daily for people capable of pregnancy, from supplements and/or fortified foods alongside a balanced diet. Begin before conception rather than waiting for prenatal care. After a previous NTD-affected pregnancy, CDC recommends 4,000 mcg (4 mg) daily starting one month before trying to conceive through the first three months of pregnancy. Coordinate this higher-dose plan with the clinician; it is distinct from the 600 mcg DFE total-intake target.
Do not let a common MTHFR variant replace prevention
Common MTHFR variants do not mean a patient cannot use folic acid. CDC does not recommend a different folic-acid amount or routine MTHFR testing on this basis. Folic acid has demonstrated NTD-prevention evidence; do not assume a supplement containing only methylfolate has equivalent prevention evidence.
Compare treatment with no treatment
Every pregnancy has a baseline risk of loss and congenital conditions. A useful assessment compares the best treatment options with the expected harm of untreated or undertreated maternal disease.
Review before and during pregnancy
Reconcile prescriptions, nonprescription products, supplements, alcohol, nicotine, and other exposures. Stop, substitute, or continue therapy only after considering withdrawal, relapse, and disease control.
Counsel about alcohol without predicting an outcome
CDC identifies no known safe amount, timing or type of alcohol during pregnancy or while trying to conceive. Explain that stopping further exposure is beneficial even after pregnancy is recognized. Prior exposure does not establish that fetal injury occurred; document the pattern, arrange prenatal follow-up and help the patient access treatment if stopping is difficult.
Offer tobacco cessation support
Ask about cigarettes, vaping and other nicotine products, and offer behavioral cessation counseling and follow-up. USPSTF gives behavioral interventions a Grade A recommendation in pregnancy; its insufficient-evidence statement for cessation medicines is not proof of harm or a blanket contraindication. Discuss medication choices individually with the prenatal team when counseling alone is inadequate. E-cigarettes are not a safe pregnancy substitute.
Do not substitute cannabis for pregnancy treatment
CDC recommends avoiding cannabis during pregnancy and breastfeeding. Changing from smoking to vaping or edibles does not establish safety. Discuss the reason for use, such as nausea, and offer treatments with appropriate pregnancy evidence. THC can enter milk and persist because it is stored in fat; brief dose timing does not reliably eliminate infant exposure. Limited CBD pregnancy data do not demonstrate safety.
Treat opioid use disorder through coordinated care
Do not instruct a pregnant patient with opioid dependence to stop abruptly. CDC recommends methadone or buprenorphine for opioid use disorder with behavioral and prenatal care, rather than withdrawal as the default strategy. Coordinate addiction, obstetric and pediatric teams. Possible neonatal withdrawal requires monitoring and treatment planning; it is not a reason to withhold effective maternal therapy. Continue prescribed treatment and reassess after delivery instead of assuming childbirth ends the indication.
Quick check
Checking for saved practice…
Lesson
Maternal Physiology and Pharmacokinetics
Pregnancy changes plasma volume, protein binding, body composition, hepatic activity, renal filtration, and gastrointestinal function in drug-specific ways.
- Plasma volume
- Albumin
- GFR
- CYP activity
- Free drug
Distribution volume can expand while albumin and total levels fall
Renal clearance often rises while hepatic effects remain enzyme specific
A pregnancy-adjusted dose can become excessive postpartum
Distribution changes
Plasma volume and total body water expand, body fat can increase, and albumin decreases. Hydrophilic drugs can have a larger apparent distribution volume, while lower binding can reduce total concentrations without a proportional fall in free drug.
Clearance changes
Renal blood flow and glomerular filtration increase early in pregnancy, which can increase clearance of renally eliminated drugs. Hepatic enzyme activity changes by pathway, so metabolism does not move uniformly in one direction.
Use observed drug-specific changes
The prospective MONEAD study found lower dose-normalized concentrations during pregnancy than postpartum for several antiseizure medicines, including lamotrigine and levetiracetam. Findings were not identical across drugs or total and unbound measurements. A population-level change is a reason for individualized monitoring, not an instruction to increase every dose by the same percentage.
Plan the postpartum transition before delivery
The 2026 MONEAD dosing analysis described individualized antiseizure-drug changes during pregnancy and the first six weeks after birth. Dose reductions often began early postpartum, but patterns differed by medicine and patient. This observational cohort does not establish a universal taper or prove that every dose should immediately return to its conception value. Arrange a documented postpartum plan with the epilepsy team, using clinical control, adverse effects and appropriately timed concentrations.
Interpret dose-normalized concentration
Concentration divided by daily dose helps compare exposure when the prescribed dose changes. In a fictional example, 6 mg/L at 300 mg/day gives 0.020 day/L; 12 mg/L at the same daily dose gives 0.040 day/L, twice the dose-normalized concentration. Check sample timing, adherence, interactions and symptoms before attributing a change to pregnancy physiology or choosing a new dose.
Measure the right signal
Use drug-specific targets, symptoms, organ function, and validated concentration monitoring when available. Pregnancy can alter dose needs over time, and postpartum reversal can make a pregnancy-adjusted dose excessive.
Quick check
Checking for saved practice…
Lesson
Placental Transfer, Structure, and Developmental Timing
Placental exposure depends on drug structure, concentration gradients, transport, protein binding, blood flow, metabolism, dose, and developmental timing.
- Passive diffusion
- Lipophilicity
- Ionization
- Protein binding
- Developmental window
Protein binding and transport also influence fetal exposure
Concentrations, blood flow, metabolism and transport shape fetal exposure
Implantation, organogenesis, growth, and neonatal adaptation create distinct questions
Read the molecule
Small, lipophilic, nonionized, weakly protein-bound compounds often diffuse more readily. Large molecules may cross less efficiently, but molecular weight is not an absolute barrier because transport mechanisms and placental integrity also matter.
Compare antibody products individually
Large biologic molecules do not all behave alike. Infliximab crosses the placenta, including during the third trimester, and can remain detectable in infants after birth. Certolizumab pegol is an antibody fragment without an Fc region; its labeling reports low or negligible transfer in studies near delivery. Low transfer does not establish absence of risk, and these observations do not justify switching an effective treatment automatically. Review the specific product, maternal disease control, timing and infant follow-up needs with the treating team.
Separate exposure from effect
Placental transfer means fetal exposure, not automatic toxicity. Effect depends on concentration, duration, target biology, maternal and fetal genetics, and the developmental process active at the time.
Interpret the early all-or-none pattern cautiously
The first two weeks after conception, approximately gestational weeks three and four, are often described as an all-or-none period: a sufficiently harmful exposure may cause loss, while surviving pregnancies generally are not expected to develop structural defects from that early exposure. Exceptions exist. Confirm the dates, drug persistence, amount and duration; do not use this pattern to guarantee a harmless outcome or ignore exposure continuing into later development.
Use developmental windows
Early exposure can affect implantation or loss, organogenesis is associated with structural-malformation risk, and later exposure can alter growth, organ function, adaptation at birth, or withdrawal. These are patterns, not guarantees.
Quick check
Checking for saved practice…
Lesson
Evidence, FDA Labeling, and Risk Communication
Current FDA prescription labeling uses narrative evidence and clinical considerations rather than the retired A, B, C, D, and X categories.
- PLLR
- Pregnancy registry
- Risk summary
- Clinical considerations
- Data limitations
Read risk summary, clinical considerations, data, and reproductive potential
Assess comparator, timing, confounding, precision, and mechanism
Separate known findings from uncertainty and background risk
Use the current label
Section 8.1 Pregnancy describes risk summary, clinical considerations, and available human or animal data. Section 8.2 Lactation addresses milk presence, effects on the breastfed child, and effects on milk production. Section 8.3 addresses pregnancy testing, contraception and infertility when relevant, including information for females and males of reproductive potential. The PLLR does not apply to OTC Drug Facts labeling; absence of these sections on an OTC product is not evidence of pregnancy safety.
Recognize older prescription formats
The requirement to remove pregnancy letter categories also applied to older prescription products, but not every older label had to adopt the newer numbered PLLR format. For a product approved before June 30, 2001, check the current full prescribing information rather than assuming that missing section numbers mean missing risk or that an old letter remains a valid clinical ranking. Use the product-specific warnings, pregnancy and nursing information, and current evidence together.
Grade the evidence honestly
Randomized pregnancy safety trials are uncommon. Registries, cohorts, case-control studies, pharmacovigilance, animal data, mechanism, and background rates each answer different questions and carry different biases.
Communicate absolute meaning
State the observed outcome, comparison group, precision, exposure timing, confounding, and what remains unknown. Avoid converting absence of evidence into evidence of no risk.
Calculate before counseling
For a hypothetical baseline of 1 event per 1,000 pregnancies and relative risk 2, the exposed estimate is 2 per 1,000. That is 0.2% versus 0.1%, an absolute increase of 0.1 percentage point, not two percentage points. A relative risk alone cannot supply an absolute rate without a baseline. These are teaching numbers, not an estimate for any particular medicine; assess study precision and confounding before applying real data.
Quick check
Checking for saved practice…
Lesson
Retinoids and Antiandrogen Exposure
Identify the product and exposure route before selecting prevention, urgent action and follow-up.
- Oral versus topical
- Pregnancy prevention
- Handling exposure
Assess actual absorption and exposure
Follow the active program and handling instructions
Use drug-specific action and counseling
Prevent oral isotretinoin exposure
Oral isotretinoin is contraindicated during pregnancy because of severe embryo-fetal toxicity, even with brief exposure. If pregnancy occurs, stop it immediately and arrange specialist reproductive-toxicity evaluation and counseling. Follow iPLEDGE pregnancy testing and prevention requirements: for patients who can become pregnant, two accepted contraceptive methods or qualifying continuous abstinence are required for one month before, during and one month after treatment. Do not donate blood during treatment or for one month afterward.
Distinguish approval from implementation
As of September 24, 2026, FDA's approved iPLEDGE modifications are scheduled for November 15, 2026, after a delay from August. Interim enforcement discretion permits prescriber-supervised home pregnancy testing during and after treatment; pretreatment testing remains in a medical setting. Confirm the active program rules before prescribing or dispensing rather than treating a future change as already operational.
Interpret topical exposure separately
Avoid topical retinoids in pregnancy, but do not tell a patient that limited topical tretinoin exposure carries the same demonstrated risk as oral isotretinoin. Absorption is lower with proper skin use and can rise with broken skin, excessive amounts or a large treated area. MotherToBaby reports reassuring studies with proper application alongside case reports and remaining uncertainty. Stop further use and review the exact product and exposure with the obstetric team; neither inevitable harm nor zero risk is justified.
Prevent unintended 5-alpha-reductase inhibitor exposure
Finasteride and dutasteride are contraindicated in pregnancy because reducing dihydrotestosterone can disrupt development of male external genitalia. Review household medicines as well as the patient's own prescriptions. Avoid handling crushed or broken finasteride tablets when pregnant or potentially pregnant; intact coating prevents contact with the active ingredient during normal handling.
Follow the capsule-specific handling warning
Dutasteride labeling advises pregnant or potentially pregnant people not to handle its capsules. If contact with a leaking capsule occurs, wash the area immediately with soap and water and seek exposure-specific advice. Wash similarly after contact with broken or crushed finasteride. Dutasteride users must avoid blood donation until at least six months after the last dose to prevent exposure of a pregnant transfusion recipient.
Quick check
Checking for saved practice…
Lesson
Antiseizure and Migraine Drugs in Pregnancy
Plan treatment before conception and coordinate changes with neurology and obstetric care.
- Seizure control
- Fetal screening
- Drug concentrations
Choose an appropriate regimen before conception
Coordinate anatomy, cardiac or growth screening as indicated
Reassess through pregnancy and postpartum
Distinguish valproate indication and urgency
Valproate increases congenital-malformation and neurodevelopmental risks. It is contraindicated for migraine prevention during pregnancy; epilepsy or bipolar use is reserved for situations where alternatives fail or are unacceptable. For epilepsy, do not abruptly discontinue it: status epilepticus can threaten parent and fetus. Arrange prompt specialist review rather than an unsupervised stop or switch. No dose can be declared free of fetal risk.
Plan antiseizure therapy before conception
The 2024 AAN/AES/SMFM guideline favors considering lamotrigine, levetiracetam or oxcarbazepine when suitable for the epilepsy syndrome and seizure-control needs, and avoiding valproate when clinically feasible. These are not interchangeable drugs. Once pregnancy is established, changing an effective regimen requires particular caution. Follow concentrations and clinical control as drug clearance changes.
Match antiseizure exposure to fetal assessment
AAN/AES/SMFM advises avoiding phenobarbital when clinically feasible to reduce cardiac-malformation risk, and phenobarbital or topiramate to reduce oral-cleft risk. Avoid topiramate or valproate when feasible to reduce small-for-gestational-age risk. Arrange anatomical fetal screening for any antiseizure exposure in a patient with epilepsy, additional fetal cardiac screening with phenobarbital, and growth surveillance with topiramate or valproate. These recommendations require a coordinated treatment plan that protects seizure control.
Explain carbamazepine risk without provoking withdrawal
Carbamazepine exposure has been associated with congenital malformations, including spina bifida. Counsel before conception and review alternatives with the epilepsy team. Discovery of pregnancy is not an instruction to stop carbamazepine abruptly: severe seizures or status epilepticus can endanger both patient and fetus. Exposure alone does not establish that an individual fetus has been harmed.
Use unbound phenytoin monitoring in pregnancy
Prenatal phenytoin exposure has been associated with oral clefts, cardiac defects and fetal hydantoin features involving craniofacial development, digits, growth and neurodevelopment. Pregnancy also changes clearance and protein binding. The label directs monitoring based on unbound phenytoin, together with clinical seizure control, rather than escalating solely to normalize a low total concentration. Reassess dosing postpartum as exposure returns toward baseline.
Separate maternal vitamin K from newborn prophylaxis
Phenytoin labeling warns of neonatal bleeding from reduced vitamin K-dependent clotting factors and describes vitamin K for the mother before delivery and the newborn afterward. RCOG's 2016 epilepsy guideline, however, finds insufficient evidence for routine maternal oral vitamin K to prevent neonatal bleeding. Discuss this labeling-guideline difference with the obstetric and neurology team rather than inventing a universal maternal dose. The uncertainty concerns maternal supplementation; it does not negate routine newborn intramuscular vitamin K, supported by the AAP. Maternal supplementation does not replace the baby's prophylaxis.
Use folate without promising complete protection
AAN/AES/SMFM recommends at least 0.4 mg folic acid daily before and during pregnancy for people with epilepsy treated with an antiseizure medication. This is a minimum recommendation, not proof that one dose suits every patient. Folic acid does not make valproate safe or eliminate the need for medication review and appropriate fetal assessment.
Avoid migraine ergots during pregnancy
Ergotamine/caffeine is contraindicated in pregnancy because of uterine-stimulating effects. Current TRUDHESA dihydroergotamine labeling advises avoiding pregnancy use because of preterm-delivery risk. Its human data do not show an increased major-malformation or miscarriage risk, but that finding does not establish overall pregnancy safety. Review an accidental exposure and arrange an appropriate migraine treatment plan rather than repeating the ergot.
Quick check
Checking for saved practice…
Lesson
Mental-Health Treatment During Pregnancy
Balance fetal and newborn effects against relapse and withdrawal, with an explicit delivery and follow-up plan.
- Relapse prevention
- Neonatal adaptation
- Lithium monitoring
Include relapse, withdrawal and patient goals
Match surveillance to the specific exposure
Plan dose changes and follow-up explicitly
Preserve effective mental-health treatment
ACOG recommends against withholding or stopping mental-health medication solely because of pregnancy or lactation. Assess illness severity, prior response, relapse risk, bipolar symptoms and patient preferences. Psychotherapy is a first-line option for mild-to-moderate perinatal depression. When medication is indicated without a prior treatment history, sertraline or escitalopram are reasonable initial choices; an effective established regimen needs individualized review.
Discuss paroxetine specifically
The cited paroxetine tablet label describes an association between first-trimester exposure and increased cardiovascular-malformation risk, with inconsistent individual-study findings. Consider other options before starting it during pregnancy planning or the first trimester. For a patient already benefiting, arrange a prescriber-obstetric review that weighs fetal evidence against relapse and withdrawal; avoid an abrupt self-directed stop.
Plan neonatal observation without routine antidepressant taper
Late SSRI exposure can be associated with neonatal adaptation symptoms and persistent pulmonary hypertension. Coordinate newborn assessment. ACOG does not recommend routinely lowering or stopping an antidepressant before delivery solely to reduce adaptation symptoms, because benefit has not been demonstrated and relapse risk increases.
Plan fetal assessment after lithium exposure
Lithium can remain appropriate when its benefit outweighs reproductive risk, particularly after a strong prior response. First-trimester exposure warrants a detailed second-trimester ultrasound with attention to cardiac anatomy; ACOG says fetal echocardiography may also be considered where available. Exposure does not establish that a malformation occurred. Coordinate psychiatric and obstetric review rather than abruptly stopping effective treatment.
Follow lithium clearance through pregnancy
Lithium is not metabolized; renal elimination governs exposure. Pregnancy can increase clearance, while postpartum changes can raise concentrations on a previously tolerated dose. Use timed levels, symptoms, kidney function and the individual's effective baseline to guide adjustments. Reassess promptly with dehydration, preeclampsia, blood loss or interacting medicines, including postpartum NSAIDs. A level alone cannot exclude toxicity.
Write an explicit lithium delivery plan
Instructions differ: the cited U.S. capsule label advises reducing or stopping lithium two to three days before expected delivery. ACOG describes some experts withholding it at labor onset or 24 to 48 hours before planned delivery. These are attributed approaches, not a universal patient-directed schedule. The obstetric and psychiatric team should document dosing, newborn observation and prompt postpartum reassessment, balancing toxicity against relapse.
Limit benzodiazepines without creating withdrawal
ACOG advises avoiding benzodiazepines or using them sparingly for perinatal anxiety. Selected short-term use may be justified while definitive treatment takes effect. Review sedation, other depressants, dependence, and newborn risks such as respiratory compromise, low muscle tone and withdrawal. A third-trimester taper is an individualized decision: worsening maternal illness can change the balance.
Individualize a benzodiazepine reduction
A patient taking a benzodiazepine regularly should not abruptly stop because pregnancy is discovered. FDA warns that abrupt cessation or rapid reduction can cause life-threatening withdrawal, including seizures, even after prescribed use. Arrange a supervised plan based on agent, dose, duration, symptoms and other substances. No single taper schedule fits every patient; a short-course example must not be applied automatically to longstanding dependence.
Quick check
Checking for saved practice…
Lesson
Cardiometabolic Drugs and Pregnancy Planning
Separate product-specific contraindications, selected specialist exceptions and changing program requirements.
- Indication
- Contraception
- Current labeling
Weight loss, lipids and arrhythmia need different plans
Check interactions and post-treatment intervals
Separate REMS changes from clinical risk
Update blanket danger lists
FDA removed the blanket pregnancy contraindication for statins in 2021, while still advising discontinuation in most pregnancies. Exceptional cardiovascular risk, such as homozygous familial hypercholesterolemia or prior myocardial infarction or stroke, warrants specialist benefit-risk review. Removing the contraindication does not endorse routine pregnancy use.
Counsel after inadvertent statin exposure
FDA advises reassurance that unintended early statin exposure is unlikely to harm the fetus. Clarify the drug, dose, dates, and maternal indication and coordinate the ongoing plan. This is not a guarantee of zero risk; observational evidence has limitations, and miscarriage risk remains uncertain.
Prevent pregnancy during phentermine/topiramate treatment
Qsymia is contraindicated in pregnancy. Topiramate exposure is associated with oral clefts and small-for-gestational-age infants. The label recommends a negative pregnancy test before starting and monthly during treatment, plus effective contraception; Qsymia retains its certified-pharmacy REMS. Do not infer that removal of another drug class's REMS applies here.
Handle Qsymia discontinuation according to the situation
For known or suspected pregnancy, Qsymia counseling directs immediate discontinuation and immediate contact with the prescriber. Abrupt topiramate withdrawal can provoke seizures even without a seizure history, so medically necessary immediate discontinuation requires appropriate monitoring. For routine discontinuation of 15 mg/92 mg, the label instead specifies every-other-day dosing for at least one week before stopping. This pregnancy instruction for an obesity combination must not be substituted for an individualized epilepsy treatment plan.
Plan semaglutide transitions before conception
Wegovy used for weight reduction should be discontinued when pregnancy is recognized; intentional weight loss offers no pregnancy benefit. Stop at least two months before a planned pregnancy for weight or cardiovascular risk reduction. Current labeling separately permits considering Wegovy for MASH with advanced fibrosis only when expected benefit justifies fetal risk; this is not evidence of fetal safety. Confirm indication and product rather than applying a weight-loss rule to every clinical circumstance.
Protect contraception during tirzepatide escalation
Zepbound should be discontinued when pregnancy is recognized. Delayed gastric emptying may reduce oral hormonal contraceptive effectiveness: use a non-oral method or add a barrier method for four weeks after starting and four weeks after each dose increase. Non-oral hormonal methods are not expected to be affected by this absorption interaction. Do not assume protection resumes immediately after a dose escalation.
Keep lomitapide separate from the statin exception
Lomitapide remains contraindicated in pregnancy. Obtain a negative pregnancy test before treatment, use effective contraception during treatment and for two weeks after the final dose, and discontinue if pregnancy is detected. Vomiting or diarrhea can undermine oral contraceptive effectiveness: its label calls for an effective alternative contraceptive method until seven days after symptoms resolve. A specialist exception considered for a statin must not be transferred to lomitapide.
Separate ERA pregnancy risk from REMS status
Endothelin receptor antagonists remain contraindicated in pregnancy. Exclude pregnancy before starting therapy and counsel on effective contraception. In 2025, FDA eliminated the ambrisentan, macitentan-containing product and aprocitentan REMS and removed pregnancy-related requirements from bosentan and sparsentan REMS. Bosentan and sparsentan retain liver-safety REMS requirements. Removal of a REMS requirement does not establish pregnancy safety or remove labeling precautions.
Prevent exposure with the exact ERA label
Bosentan and ambrisentan labeling calls for contraception before treatment, throughout treatment and for one month afterward. If pregnancy occurs, the labels direct discontinuation as soon as possible; urgently coordinate with the PAH team for alternative treatment and maternal-fetal assessment. Bosentan reduces hormonal contraceptive exposure, so oral, injectable, transdermal or implantable hormonal contraception alone is insufficient. Review an additional method and the exact product instructions.
Distinguish amiodarone risk from emergency care
Amiodarone is generally avoided in pregnancy, but serious arrhythmias require a specialist benefit-risk decision rather than automatic withholding of lifesaving care. Reported fetal and newborn effects include thyroid dysfunction, bradycardia, impaired growth and neurodevelopmental abnormalities. After exposure, arrange neonatal thyroid and cardiac assessment. HRS guidance supports indicated cardioversion or defibrillation during pregnancy; fetal-risk counseling must not delay stabilization.
Read current dronedarone reproductive labeling
The current MULTAQ label warns of fetal harm based on animal malformations and lacks human pregnancy outcome data. Unlike older labeling, pregnancy is not listed in its contraindications section; that change does not establish pregnancy safety. Verify absence of pregnancy before starting, use effective contraception during treatment and for five days after the last dose, and promptly report suspected pregnancy for specialist review. Do not substitute dronedarone for amiodarone on an assumption of reproductive safety.
Quick check
Checking for saved practice…
Lesson
Immune and Hematology Drugs in Pregnancy
Verify the treated person, indication, conception timing and product-specific testing or elimination requirements.
- Exposure role
- Washout
- Restricted programs
Do not apply one reproductive rule to both roles
Use the exact drug protocol and interval
Selected specialist decisions do not prove fetal safety
Separate methotrexate indications
Methotrexate tablets are contraindicated during pregnancy for non-neoplastic diseases such as rheumatoid arthritis and psoriasis. Exposure can cause fetal death and developmental injury. Suspected pregnancy needs immediate prescriber and obstetric review. Cancer treatment requires an individualized oncology-obstetric decision; its different labeling does not imply fetal safety.
Attribute methotrexate planning intervals
The cited U.S. tablet label requires pregnancy testing before treatment and effective contraception during therapy, then six months after the last dose for females and three months for males with partners who could become pregnant. EULAR's 2024 reproductive update instead recommends stopping maternal methotrexate one to three months before conception and permits paternal treatment up to 25 mg weekly. Identify the exposure role, product and specialist plan rather than combining these recommendations into one rule.
Verify leflunomide elimination
Leflunomide is contraindicated in pregnancy. Its active metabolite, teriflunomide, may persist for up to two years without accelerated elimination. Pregnancy requires stopping treatment and prompt specialist-directed elimination. The label uses oral cholestyramine 8 g three times daily for 11 days, or activated charcoal suspension 50 g every 12 hours for 11 days. Confirm plasma teriflunomide below 0.02 mg/L on two tests at least 14 days apart; repeat elimination when needed. Continue contraception until verified clearance when planning pregnancy. Completing eleven treatment days alone does not establish clearance.
Individualize hydroxyurea decisions in sickle-cell pregnancy
Hydroxyurea labeling warns of fetal harm. WHO 2025 guidance nevertheless allows consideration of continuing treatment or restarting after the first trimester in patients whose sickle-cell disease was previously controlled with it. The patient and a team with pregnancy and sickle-cell expertise should weigh disease severity, gestational timing, alternatives and patient preferences. Limited observational evidence does not establish fetal safety; this is a selected clinical decision, not routine pregnancy use.
Check the exact hydroxyurea product before conception
Verify pregnancy status before starting therapy. SIKLOS labeling requires effective contraception during treatment and for at least six months afterward for female patients and male patients with partners who can become pregnant. HYDREA specifies at least six months afterward for female patients but at least one year for male patients. Confirm the dispensed product rather than transferring one label interval to every formulation.
Prevent thalidomide and lenalidomide fetal exposure
Thalidomide and lenalidomide are contraindicated in pregnancy and require their restricted distribution programs. Thalidomide can cause severe malformations even after a single capsule. For patients who can become pregnant, use two approved contraceptive methods together, including one highly effective method, or qualifying continuous abstinence. Begin precautions four weeks before treatment and continue through treatment, interruptions and four weeks afterward. Suspected pregnancy requires stopping the drug and immediate specialist evaluation.
Schedule testing rather than relying on a single result
The cited THALOMID and REVLIMID labels require two negative pretreatment pregnancy tests: one 10 to 14 days before prescribing and another within the preceding 24 hours. Test weekly for the first four weeks, then every four weeks with regular cycles or every two weeks with irregular cycles, including during interruptions. Missed periods or abnormal bleeding require evaluation; continue to follow the active product program's testing and dispensing requirements.
Include male patients and donation precautions
Thalidomide and lenalidomide enter semen. Male patients need latex or synthetic condoms for sexual contact with partners who can become pregnant during treatment, interruptions and four weeks afterward, even after vasectomy. Do not donate sperm during treatment; REVLIMID explicitly extends this restriction four weeks afterward. Neither drug permits blood donation during treatment or for four weeks afterward. Verify all requirements with the applicable program.
Quick check
Checking for saved practice…
Lesson
Hormones and Reproductive-Care Indications
Distinguish intentional reproductive treatment from unintended exposure and unrelated hormone products.
- Progesterone support
- Misoprostol indication
- Secondary transfer
Progesterone, megestrol and testosterone are different
Separate reproductive protocols from other uses
Prevent unintended exposure and skin transfer
Separate misoprostol indications
Misoprostol must not be used to prevent NSAID-induced ulcers during pregnancy. Its uterine effects can cause pregnancy loss, premature delivery and uterine rupture; the label reports congenital abnormalities after unsuccessful abortion attempts. If pregnancy occurs during ulcer-prevention treatment, stop that treatment and arrange prompt evaluation. Uterine-rupture risk increases with advancing gestation and prior uterine surgery.
Recognize intentional reproductive uses
The ulcer-prevention warning does not mean misoprostol has no appropriate reproductive use. WHO recommends misoprostol-containing regimens for medical abortion and medical management of pregnancy loss. The indication, gestational age, uterine history, route, dose, patient preferences and access to assessment determine the plan. Do not substitute a gastrointestinal dosing schedule for a reproductive-care regimen or label all obstetric use a medication error.
Counsel after inadvertent contraceptive exposure
Combined hormonal contraceptives are unnecessary during an established pregnancy. CDC reports no known harm to the patient, pregnancy course or fetus from inadvertent use. Stop the contraceptive and review the actual product and exposure with the prenatal team; do not interpret an old hormone danger list as proof of fetal injury. This reassurance is specific to combined contraception and does not establish safety for unrelated hormone treatments.
Do not classify all hormones together
Progesterone is not universally forbidden in pregnancy. Endometrin vaginal progesterone is labeled for implantation and early-pregnancy support in an ART program for infertile patients younger than 35; its efficacy and dose at older ages are not established in labeling. Use the prescribed reproductive protocol rather than stopping luteal support because a general danger list includes hormones. Different progestogens, formulations, routes, and indications are not interchangeable.
Do not substitute megestrol for pregnancy-support progesterone
Megestrol acetate oral suspension is contraindicated in pregnancy; animal findings support fetal risk, while human outcome data are inadequate. Obtain a negative pregnancy test before starting and use effective contraception during treatment. Its progestational activity does not make it an alternative to vaginal micronized progesterone for a defined reproductive indication. Chronic megestrol can also suppress adrenal function, so exposure and withdrawal require a clinician-directed plan.
Recognize menopausal products with pregnancy contraindications
Raloxifene and Duavee are contraindicated in pregnancy and are not indicated for patients of reproductive potential. Duavee combines conjugated estrogens with bazedoxifene; it is not progesterone support. Limited human exposure data do not permit assurance of safety or a prediction of certain harm. Confirm the product and promptly coordinate assessment of an inadvertent exposure.
Prevent secondary testosterone exposure
Testosterone gel is contraindicated in pregnancy and can virilize a female fetus. Exposure can come from another person's application site. The cited 1.62% gel label instructs users to wash hands after application, cover the site after drying, and wash the site before anticipated skin contact. After accidental contact with an unwashed or uncovered site, wash the exposed person's skin promptly with soap and water and obtain exposure-specific advice. Follow the exact formulation instructions.
Distinguish miscarriage guidance from ART support
UK NICE NG126 recommends vaginal micronized progesterone 400 mg twice daily for scan-confirmed intrauterine pregnancy with bleeding and a previous miscarriage; if a fetal heartbeat is confirmed, continue until 16 completed weeks. This is a defined UK recommendation, not routine supplementation for every pregnancy or a substitution for Endometrin's ART regimen. Bleeding or pain requires assessment of pregnancy location and viability.
Quick check
Checking for saved practice…
Lesson
Vaccination Before, During, and After Pregnancy
Vaccine selection depends on product, gestational timing, season, prior doses, immunity, and exposure risk.
- Influenza
- Tdap
- Maternal RSV
- Live vaccines
- Travel
Tdap and maternal RSV have different repeat-dose rules
Check the vaccine-specific window and local guidance
Document the maternal plan and infant RSV handoff
Plan influenza and Tdap
Use inactivated or recombinant influenza vaccine seasonally in any trimester; avoid live nasal influenza vaccine. Give Tdap during each pregnancy, preferably early in weeks 27 to 36. Earlier administration can be appropriate for wound management or a community pertussis outbreak. If Tdap was already given during this pregnancy, do not repeat it at 27 to 36 weeks; distinguish this from a dose before conception.
Use the current COVID-19 season guidance
CDC's September 23, 2026 clinical guidance recommends a 2026-2027 COVID-19 vaccine for all adults aged 18 years or older. For younger patients, recommendations depend on age and immune status; do not automatically apply the adult recommendation to a pregnant adolescent. CDC's February 2026 pregnancy page still describes the earlier 2025-2026 individual-decision framework. Identify the date and season when reconciling these sources. ACOG recommends vaccination during pregnancy, which increases severe-COVID risk. Assess the current product, prior doses, immune status and contraindications; distinguish a clinical recommendation from its FDA-approved indication. Pregnancy safety evidence is reassuring, but does not guarantee zero adverse effects. Breastfeeding does not require interruption for vaccination.
Assess hepatitis and deferred vaccines
Pregnancy does not preclude hepatitis B vaccination when indicated; CDC recommends vaccination for unvaccinated adults aged 19 through 59, including during pregnancy. Hepatitis A vaccination is recommended for pregnant patients at increased infection risk or risk of severe outcomes, such as those with chronic liver disease. Review prior doses and the product-specific schedule. Defer remaining HPV doses until after pregnancy; an inadvertently administered dose does not require intervention.
Do not delay indicated rabies prevention
After a possible rabies exposure, promptly arrange wound care and public-health risk assessment. Pregnancy is not a contraindication to indicated post-exposure prophylaxis. Prior rabies vaccination and immune status determine the vaccine and immune-globulin regimen; neither vaccine alone nor waiting until delivery is an adequate blanket plan.
Match maternal RSV product and timing
CDC recommends Abrysvo at 32 weeks 0 days through 36 weeks 6 days, during September through January in most of the continental US. Follow local timing where seasonality differs. Arexvy and mResvia are not pregnancy substitutes. Beyond this gestational window, arrange infant RSV protection instead.
Review prior maternal RSV vaccination
CDC does not currently recommend repeating maternal RSV vaccine in subsequent pregnancies. Coordinate infant antibody protection if a prior pregnancy's vaccination was the only maternal dose. Most infants need either maternal vaccination or infant antibody protection, not both.
Coordinate newborn RSV protection
Nirsevimab or clesrovimab provides passive antibody protection, not vaccination. CDC recommends an infant antibody for eligible infants younger than 8 months entering their first RSV season when maternal vaccination was absent, unknown, or too close to birth. Birth less than 14 days after maternal vaccination requires infant protection; most infants born at least 14 days afterward do not need both. Consider exceptions for impaired maternal immune response or antibody transfer, antibody loss after bypass, or substantial infant risk. In most continental US settings, administer during October through March, ideally within a week of birth for eligible infants born in that window; follow local seasonal guidance. Second-season eligibility and products differ and require separate pediatric assessment.
Match infant RSV dose to product
For eligible first-season infants younger than eight months, CDC specifies nirsevimab 50 mg when weight is below 5 kg or 100 mg at 5 kg or more. Clesrovimab uses 105 mg regardless of weight in eligible infants. These are different products, not interchangeable milligram doses. Verify product, age, weight and eligibility before administration.
Assess second-season eligibility separately
For selected high-risk children aged 8 to 19 months entering a second RSV season, CDC recommends nirsevimab 200 mg as two 100 mg injections. Eligible groups include severe immunocompromise; chronic lung disease of prematurity requiring chronic corticosteroids, diuretics or supplemental oxygen within six months before the season; cystic fibrosis with severe lung disease or weight-for-length below the tenth percentile; and American Indian or Alaska Native children. Clesrovimab is not recommended for second-season protection. Maternal vaccination does not replace this separate eligibility assessment.
Distinguish contraindications from precautions
MMR and varicella are contraindicated during pregnancy; plan indicated vaccination afterward. Inadvertent administration is not itself a reason to terminate pregnancy. Yellow fever is a precaution: unavoidable travel with greater infection risk can justify vaccination after assessment; otherwise a medical waiver may be appropriate.
Quick check
Checking for saved practice…
Lesson
Common Symptoms and Self-Care
Constipation, reflux, nausea, vomiting, and hemorrhoids are common, but severity, hydration, weight trajectory, bleeding, pain, and alternate diagnoses determine whether self-care is appropriate.
- Nonpharmacologic care
- Doxylamine pyridoxine
- Antacids
- Laxatives
- Red flags
Assess hydration, weight, bleeding, pain, fever, and alternate diagnoses
Use current pregnancy-compatible nonpharmacologic and medication options
Set a time to reassess and clear reasons to seek urgent care
Treat nausea systematically
Small frequent meals and trigger reduction may help. Pyridoxine can be tried first and doxylamine added when needed. Persistent vomiting, dehydration, electrolyte disturbance, weight loss, or abdominal findings require clinical assessment.
Use the exact nausea formulation
Diclegis delayed-release contains doxylamine/pyridoxine 10/10 mg per tablet. Start two tablets at bedtime; if symptoms persist into day 2 afternoon, retain that bedtime dose and add one morning tablet on day 3. If still inadequately controlled, add one mid-afternoon tablet on day 4: maximum four daily. Bonjesta extended-release contains 20/20 mg per tablet: start one at bedtime, increasing on day 2 if needed to one morning and one bedtime tablet, maximum two daily. Do not copy tablet counts between products.
Counsel beyond the dose
Both prescription combinations are scheduled daily, swallowed whole with water on an empty stomach, and reassessed as pregnancy progresses. Do not crush, split, or use only as needed. Review hypersensitivity, MAO inhibitors, anticholinergic conditions and sedating co-medications. Avoid alcohol and other CNS depressants; driving requires clinician clearance. Neither product has been studied in hyperemesis gravidarum.
Recognize hyperemesis without waiting for ketones
Severe early-pregnancy nausea or vomiting that prevents normal eating and drinking and markedly restricts daily activities can indicate hyperemesis gravidarum. RCOG no longer requires a weight-loss, dehydration and electrolyte-abnormality triad. Urine ketones should not grade its severity. Assess intake, function, vital signs, weight and alternative diagnoses; inability to retain fluids or essential medicines needs prompt assessment.
Prevent nutritional and fluid complications
Hospital treatment includes appropriate antiemetics, sodium chloride 0.9% and electrolyte replacement guided by laboratory results and renal status. RCOG recommends thiamine for patients admitted with vomiting or severely reduced intake, especially before planned dextrose or parenteral nutrition. Confusion, eye-movement abnormalities or ataxia raise concern for Wernicke encephalopathy and require urgent treatment. Oral medication failure may require another route.
Discuss acetaminophen evidence accurately
ACOG's September 2025 advisory continues to identify acetaminophen as the preferred analgesic and antipyretic in pregnancy. FDA's September 22, 2025 communication raised a possible association with neurodevelopmental outcomes but explicitly stated that causation has not been established and that contrary studies exist. Do not teach that an association proves harm or promise zero risk. Assess the pain or fever, discuss appropriate use with the obstetric team, follow the exact product's dose limits, and avoid duplicate acetaminophen ingredients. Untreated high fever also carries risk.
Apply gestational NSAID precautions
Avoid self-treatment with NSAIDs from 20 weeks because fetal renal effects can reduce amniotic fluid. If a clinician deems treatment necessary between 20 and 30 weeks, minimize dose and duration; consider amniotic-fluid ultrasound when treatment exceeds 48 hours and discontinue for oligohydramnios. At 30 weeks and later, avoid NSAIDs because premature ductus arteriosus closure is an additional risk. Prescribed aspirin 81 mg for an obstetric indication is an exception; do not discontinue that plan merely because of the general NSAID warning.
Treat allergic rhinitis by symptom and route
Begin with allergen reduction and saline. If needed, consider local therapy such as an intranasal corticosteroid for persistent nasal symptoms or ocular cromolyn for eye symptoms. Budesonide has established pregnancy experience; other intranasal options may also be appropriate. Do not interpret the book's cromolyn-first sequence as mandatory for every symptom pattern.
Choose an oral antihistamine deliberately
NHS SPS prefers loratadine or cetirizine when oral treatment is needed; chlorpheniramine is an option when a sedating agent is appropriate. Pregnancy does not make sedation desirable. Assess driving, other sedatives, response and gestational context rather than requiring a first-generation drug or treating second-generation agents as universally prohibited early in pregnancy.
Check decongestants separately
ACOG advises against pseudoephedrine during the first three months. ACAAI advises clinician review and caution later, particularly with hypertension or preeclampsia; UK guidance avoids decongestants throughout pregnancy. These are differently framed recommendations, not proof of routine safety after the first trimester. Inspect combination allergy products for an added decongestant.
Assess cough products by ingredient
For OTC cough treatment used as directed, MotherToBaby does not expect dextromethorphan to increase birth-defect risk. Evidence does not establish every pregnancy outcome or the safety of every combination. Check all active and inactive ingredients, avoid alcohol-containing liquids, and select only ingredients needed for the symptoms. Prescription dextromethorphan combinations require their own assessment.
Apply the cough product instructions
For the cited alcohol-free Delsym extended-release suspension, each 5 mL supplies the equivalent of 30 mg dextromethorphan hydrobromide. Its adult directions are 10 mL every 12 hours, at most 20 mL in 24 hours; shake and use the supplied cup. This schedule does not apply to every formulation. The label requires professional review during pregnancy or breastfeeding and prohibits use with an MAOI or within two weeks after stopping one. Chronic or mucus-heavy cough needs assessment before use; stop and seek review for cough lasting over seven days, recurring, or accompanied by fever, rash or persistent headache.
Describe guaifenesin uncertainty honestly
Guaifenesin is an expectorant, not a cough suppressant. MotherToBaby finds no expectation of a large birth-defect increase, but some studies suggest small risks and miscarriage and other outcome data are limited. Breastfeeding transfer and effects have not been adequately studied. Review the need, formulation and alternatives; choose alcohol-free products and avoid describing absence of data as proof of safety.
Maintain asthma control
Continue effective inhaled corticosteroid-containing treatment during pregnancy. GINA recommends reassessment every 4 to 6 weeks and favors postponing routine step-down until after pregnancy. Review symptoms, attacks, inhaler technique, adherence and the written action plan. A short-acting bronchodilator relieves bronchospasm but does not replace anti-inflammatory protection.
Treat worsening asthma promptly
An exacerbation needs timely assessment and treatment to protect maternal and fetal oxygenation; pregnancy is not a reason to withhold usual indicated acute asthma care. Coordinate respiratory and obstetric teams. Severe breathlessness, difficulty speaking, exhaustion or inadequate response to the prescribed reliever requires urgent care.
Treat an attack rather than withholding steroids
GINA 2026 advises treating pregnancy exacerbations as in other adults. Acute care uses inhaled albuterol, oxygen when needed, and systemic corticosteroids for more than mild attacks; ipratropium is added for moderate attacks or inadequate initial response. A usual adult oral course is prednisolone 40 to 50 mg each morning for five to seven days. Severe attacks need emergency transfer; drowsiness, confusion or a silent chest signals critical illness. Continue ICS-containing treatment and arrange follow-up within two to seven days after discharge. This is clinician-directed acute care, not a replacement for assessment.
Manage reflux deliberately
Use meal timing, positional strategies, and an appropriate antacid or acid-suppressive option when needed. Check ingredients, renal function and interactions. Legacy ranitidine was withdrawn, but FDA approved reformulated tablets in November 2025. That approval does not establish pregnancy preference; use current pregnancy evidence and the exact product labeling.
Make reflux advice actionable
Try smaller meals, avoid eating during the three hours before bed, remain upright after meals, and elevate the head and shoulders for nocturnal symptoms. Identify personal food triggers. An appropriate antacid or alginate may help; calcium carbonate is an option identified in RxPrep, but check the exact product and total calcium intake. NHS guidance advises separating antacids from iron or folic acid by at least two hours. Other medicines can require different spacing. Persistent symptoms despite these measures warrant clinician-directed acid suppression; dysphagia, bleeding, weight loss or persistent vomiting requires assessment.
Check the entire gas-relief product
Simethicone acts within the gastrointestinal tract and is not orally absorbed. The UK WindSetlers labeling anticipates no adverse pregnancy effects on that basis, while retaining caution; LactMed requires no special breastfeeding precautions for simethicone itself. This supports an option for uncomplicated gas symptoms, not proof that every combination is suitable. Review all ingredients and interactions. For example, Maalox Plus adds aluminum and magnesium antacids and its pregnancy labeling requires a benefit-risk assessment. Persistent or severe abdominal pain requires assessment rather than repeated gas treatment.
Review antacid formulation and mineral burden
Do not select a product from its brand name alone. The UK Gaviscon Double Action Mint chewable formulation contains alginate, sodium bicarbonate and calcium carbonate; its label permits use during pregnancy when clinically needed. It also cautions about sodium restriction, hypercalcemia and calcium-containing stones. This formulation-specific recommendation does not endorse household baking soda or unrestricted antacid use. Check country, formulation, dose, renal function, total mineral intake and interacting medicines.
Address bowel symptoms
Review stool pattern, diet, fluids, mobility and constipating medicines, including iron, without independently stopping needed supplementation. Gradually increase dietary fiber with adequate fluids and activity as tolerated. If insufficient, consider a bulk-forming agent such as psyllium or methylcellulose with adequate water; persistent hard stools may require an osmotic agent such as polyethylene glycol or lactulose. UKTIS describes bulk agents as commonly tried first, followed by osmotics. Select the exact product and follow its dosing instructions. Rectal bleeding, severe pain, vomiting, obstruction symptoms or failure of treatment requires reassessment.
Escalate constipation treatment after reassessment
If diet, activity, adequate fluids and appropriate bulk-forming or osmotic treatment have not helped, review the diagnosis and regimen. UKTIS describes stimulant agents such as senna or bisacodyl as later options; the theoretical concern about uterine contractions has not been observed in pregnant patients. Their place after initial options does not mean they are universally contraindicated. Glycerin suppositories may be considered when other measures fail. Use a clinician- or pharmacist-directed plan rather than repeatedly adding products without assessing symptoms.
Name the diagnostic standard
Pregnancy anemia thresholds are guideline-dependent. WHO 2024 uses hemoglobin below 11 g/dL in the first trimester and below 10.5 g/dL in the second; FIGO 2025 recommends below 11 g/dL throughout pregnancy. Thus a second-trimester value of 10.7 g/dL meets FIGO's definition but not WHO's second-trimester cutoff. Neither classification establishes iron deficiency by itself. Evaluate iron stores, blood-loss history and other causes rather than treating every low hemoglobin result as iron deficiency.
Screen and establish the cause
FIGO recommends a CBC at booking and again at 28 weeks. In a patient with anemia, ferritin below 30 mcg/L supports iron deficiency. A low ferritin without low hemoglobin is iron deficiency, not automatically iron-deficiency anemia. WHO uses a different first-trimester ferritin threshold of 15 mcg/L for apparently healthy pregnant patients. Identify the guideline and clinical context; inflammation can raise ferritin and complicate interpretation.
Continue long enough to restore stores
Under FIGO guidance, once hemoglobin reaches at least 11 g/dL, reduce treatment to 30 to 60 mg elemental iron daily and continue for at least three months or through six weeks postpartum, whichever is longer. Hemoglobin recovery alone does not prove replenished stores. Record the planned reassessment and stop date rather than stopping at delivery.
Separate iron treatment from prenatal nutrition
Confirmed iron-deficiency anemia needs a treatment plan, not just a prenatal vitamin. FIGO 2025 recommends oral elemental iron 60 to 120 mg daily initially. Interpret CBC and iron studies in context and check the actual elemental content, tolerance, interactions and response. The 27 mg total daily nutritional target is a different quantity and purpose.
Reassess anemia before delivery
FIGO identifies inadequate response as a hemoglobin rise below 1 g/dL at two weeks or below 2 g/dL at four weeks of oral treatment. Review adherence, absorption, ongoing loss and alternative diagnoses. IV iron may be appropriate after the first trimester for intolerance, inadequate response, malabsorption or a need for faster correction near delivery. It is not routine first-trimester treatment. Severe bleeding or circulatory compromise requires urgent assessment, not a trial of oral supplementation.
Quick check
Checking for saved practice…
Lesson
Infections During Pregnancy
Choose treatment by infection site, culture, gestational timing and product restrictions; a general pregnancy safety reputation does not establish antimicrobial effectiveness.
- Urine culture
- Resistance
- Renal penetration
- Topical azoles
- Toxoplasmosis
Fever and flank pain change the treatment setting and required tissue exposure
Check resistance, term restrictions and the exact product
Toxoplasmosis prevention extends beyond avoiding the litter box
Screen and target urinary infection
Obtain a urine culture early in prenatal care. ACOG recommends treating asymptomatic bacteriuria at 100,000 CFU/mL or higher and acute cystitis with targeted therapy, generally for 5 to 7 days. Avoid empiric ampicillin or amoxicillin because E. coli resistance is common; susceptibility can change the choice.
Keep GBS bacteriuria on the delivery plan
Asymptomatic GBS bacteriuria below 100,000 CFU/mL does not by itself require antepartum antibiotics, but any GBS urine finding during pregnancy should be documented for intrapartum prophylaxis planning. Treat symptomatic infection or significant bacteriuria as indicated; treatment now does not erase the later prophylaxis indication. GBS-specific prophylaxis is not required for cesarean birth before labor with intact membranes; routine surgical prophylaxis is a separate decision.
Plan follow-up without inventing certainty
After acute cystitis treatment, ACOG allows either considering a repeat urine culture in one to two weeks or evaluating if symptoms recur; evidence does not establish one mandatory strategy. Recurrent symptoms or fever need reassessment. Evidence is also insufficient to mandate repeat screening after successful treatment of an initial asymptomatic episode.
Respect infection site and gestation
Fever with flank pain suggests pyelonephritis: initial inpatient treatment requires renal-tissue-active antibiotics, with 14 total treatment days under ACOG guidance. Nitrofurantoin and fosfomycin do not provide adequate kidney-tissue treatment. Nitrofurantoin or sulfonamides may be reasonable in the first trimester when appropriate alternatives are unavailable.
Verify the nitrofurantoin formulation
The Macrobid monohydrate/macrocrystal label uses one 100 mg capsule orally every 12 hours for seven days, taken with food. Do not assume other nitrofurantoin formulations share that schedule. Use a culture-appropriate lower-tract regimen only after reviewing gestational timing, renal function, allergy and G6PD status; this dose does not make nitrofurantoin suitable for pyelonephritis.
Recognize the single-dose fosfomycin exception
For an appropriate adult acute-cystitis indication, oral fosfomycin tromethamine supplies 3 g of fosfomycin as one sachet taken once. Dissolve the whole sachet in 3 to 4 fluid ounces of non-hot water and drink immediately; do not swallow dry granules. The label advises against repeated daily doses for one acute-cystitis episode and calls for cultures before and after treatment. Reconcile that product instruction with the individualized pregnancy follow-up plan. Persistent symptoms need reassessment, not automatic sachet repetition; fever or flank pain requires evaluation for upper-tract disease.
Check nitrofurantoin exclusions
Avoid nitrofurantoin with G6PD deficiency. The Macrobid label contraindicates use at term, 38 to 42 weeks, during labor/delivery or when labor is imminent because of neonatal hemolysis risk. A broad statement that a drug can be used later in pregnancy does not override these product restrictions.
Distinguish TMP-SMX treatment from prevention
NIH recommends TMP-SMX for active HIV-associated Pneumocystis pneumonia during pregnancy, including the first trimester; treatment benefit outweighs potential fetal risk. First-trimester prophylaxis can instead use atovaquone or aerosolized pentamidine. Do not transfer a prevention alternative automatically to active disease.
Use the correct folate supplement
For TMP-SMX exposure, NIH advises considering folic acid 4 mg/day before conception or early in pregnancy, limiting the high dose to the first trimester. This does not guarantee prevention of birth defects. Leucovorin is not interchangeable: adding it to TMP-SMX for PCP has increased treatment failure and death. Arrange fetal anatomy ultrasound at 18 to 20 weeks.
Check telavancin reproductive precautions
Vibativ labeling warns of fetal harm based on animal findings. Verify pregnancy status before treatment and use effective contraception during treatment and for two days after the final dose. Human data cannot establish fetal safety. If pregnancy occurs, urgently reassess the infection, alternatives and benefit-risk balance with the treating team; do not interpret an animal finding as proof of injury in an individual pregnancy.
Prevent maternal and paternal ribavirin exposure
Ribavirin is contraindicated in pregnant patients and in male patients whose partners are pregnant. Animal evidence shows major reproductive toxicity, and slow intracellular clearance extends precautions beyond the last dose. Confirm a negative pregnancy test before starting when applicable, arrange the product's ongoing testing and contraception plan, and urgently report pregnancy during the exposure window. Limited registry observations cannot establish safety.
Verify ribavirin intervals against the exact label
The cited Aurobindo capsule label requires effective contraception during treatment and for nine months afterward for female patients, versus six months for male patients and their partners; it specifies periodic pregnancy testing through the nine-month interval for female patients. The cited tablet label instead specifies two reliable contraceptive methods and monthly pregnancy testing during treatment and for six months afterward. AASLD/IDSA HCV guidance also describes six months. Record the product, exposure role, last dose and specialist plan; do not shorten a longer product-label interval by applying a generic six-month rule.
Interpret aminoglycoside warnings by agent
Systemic aminoglycosides cross the placenta. The gentamicin label cites irreversible congenital hearing loss reported after maternal streptomycin, while retaining a fetal-harm warning for the class. Do not present these reports as proof that every gentamicin exposure causes deafness or that other agents have no risk. Assess the infection, susceptibility, alternatives, route and duration with the treating team.
Keep necessary aminoglycoside treatment monitored
UKTIS reserves systemic use for situations without suitable alternatives with adequate pregnancy data and prefers gentamicin when an aminoglycoside is indicated because pregnancy experience is greater. Monitor maternal renal function, appropriately timed drug concentrations and auditory or vestibular symptoms under the selected regimen. Eye or ear preparations usually produce much less systemic exposure; their risks cannot be inferred directly from prolonged injected therapy. For TB specifically, CDC lists streptomycin, amikacin and capreomycin as contraindicated in pregnancy: coordinate treatment with a TB specialist rather than substituting within the class.
Interpret systemic fluconazole exposure precisely
Prolonged first-trimester fluconazole at 400 to 800 mg daily has been associated with a distinct malformation pattern in case reports. Lower-dose observational findings also raise concern but have limitations. A single accidental 150 mg dose is not equivalent to prolonged high-dose exposure and does not establish fetal injury. Review dose, dates and indication with the obstetric team. This distinction does not change CDC's recommendation to use seven-day topical azoles for pregnancy vaginal candidiasis. Severe invasive infection requires a separate specialist benefit-risk decision.
Review voriconazole before conception
Voriconazole labeling warns of fetal harm from animal evidence and lacks human pregnancy data. Use effective contraception during treatment and promptly review pregnancy or conception plans with infectious-disease and obstetric specialists. Do not extrapolate the compatibility of topical vaginal azoles to systemic voriconazole, or interrupt essential invasive-infection treatment without an urgent replacement plan.
Apply griseofulvin reproductive precautions
Griseofulvin is contraindicated during pregnancy. It can reduce estrogen-containing oral contraceptive effectiveness, so arrange an additional or alternative method rather than assuming the usual pill remains sufficient. The cited microsize tablet label also instructs male patients to wait at least six months after treatment before fathering a child. Distinguish maternal exposure, paternal planning and drug interactions; an exposure report alone cannot predict an individual pregnancy outcome.
Treat vaginal candidiasis specifically
Confirm that symptoms fit candidiasis rather than assuming all discharge is yeast. CDC recommends a topical azole course lasting seven days during pregnancy; do not substitute routine oral fluconazole, including a single 150 mg dose. Persistent symptoms or pelvic pain, fever or bleeding need reassessment.
Do not delay effective RMSF treatment
CDC recommends doxycycline for suspected Rocky Mountain spotted fever during pregnancy. Start presumptive treatment promptly rather than waiting for confirmatory testing or substituting a less effective agent because of a class warning. Explain the uncertainty in fetal-risk data alongside the danger of untreated infection.
Interpret fluoroquinolone evidence precisely
Current ciprofloxacin labeling reports no identified pregnancy-associated increase in major birth defects, miscarriage, or adverse maternal/fetal outcomes in available observational evidence, while emphasizing study limitations. This does not prove zero risk or make ciprofloxacin a routine first choice. Select by infection, susceptibility, alternatives, and its substantial nonpregnancy safety warnings; avoid labeling all exposures proven teratogenic.
Prevent toxoplasmosis exposure
Cook meat to the appropriate food-safety temperature, wash produce and food-preparation surfaces, avoid untreated water and unpasteurized goat milk, and wear gloves for gardening. Have another person change cat litter daily if possible; otherwise use disposable gloves and wash hands. Feed cats commercial food, not raw meat. Food and soil exposure matter as well as litter.
Quick check
Checking for saved practice…
Lesson
Thyroid Replacement and Antithyroid Treatment
Pregnancy thyroid care requires early testing, diagnosis-specific dose adjustment and attention to both maternal control and fetal exposure.
- Levothyroxine
- Prenatal interaction
- Overt versus subclinical
- PTU
- Postpartum reassessment
A standard increase does not fit every levothyroxine-treated patient
Separate iron/calcium prenatal products by at least four hours
Monitor after treatment changes and revisit doses after delivery
Individualize replacement
Established overt hypothyroidism commonly requires an early levothyroxine increase, followed by laboratory titration. ATA 2026 emphasizes prior TSH and dose when choosing the increase; do not automatically apply a fixed 30 to 50 percent increase to everyone. For preconception subclinical hypothyroidism, evidence does not support a universal 25 percent increase at a positive pregnancy test.
Translate a weekly plan
One established adjustment strategy is two additional usual daily doses each week. For 100 mcg daily, seven doses provide 700 mcg/week; nine provide 900 mcg/week, a 28.6 percent increase. This arithmetic illustrates a prescribed plan, not an automatic instruction for every patient.
Protect absorption and monitoring
Separate levothyroxine from iron/calcium-containing prenatal vitamins by at least four hours. Check thyroid function approximately every four weeks during the first half of pregnancy. After delivery, the pre-pregnancy replacement dose can often be resumed, with testing around six weeks; reassess individually.
Choose antithyroid therapy by phase
PTU is preferred when antithyroid medication is needed in the first trimester. After 16 weeks, ATA 2026 identifies no preferred agent: weigh adverse effects and the risk of destabilization when switching. Continued treatment needs TSH/free T4 monitoring every two to four weeks. Radioactive iodine is not a pregnancy treatment.
Quick check
Checking for saved practice…
Lesson
Diabetes in Pregnancy
Preexisting diabetes and gestational diabetes require coordinated nutrition, monitoring, medication, fetal assessment, and postpartum follow-up.
- Screening
- Glucose targets
- Insulin
- Placental transfer
- Postpartum testing
Interpret each reading against its time-specific target
For GDM, add insulin when needed; teach hypoglycemia care
Reassess insulin after delivery; arrange OGTT and ongoing screening after GDM
Diagnose and monitor
Evaluate for overt diabetes early when indicated and screen for gestational diabetes at 24 to 28 weeks if not already diagnosed. Common treatment targets are fasting below 95 mg/dL, one hour below 140, and two hours below 120.
Select therapy
Nutrition and behavioral treatment are foundational. Insulin is the preferred medication when targets are not met. Metformin and glyburide cross the placenta and are not first-line substitutes for insulin under ADA guidance.
Balance targets with hypoglycemia
ADA's pregnancy A1C goal is below 6 percent when achievable without significant hypoglycemia; below 7 percent may be appropriate to prevent hypoglycemia. A1C does not replace fasting and postmeal monitoring.
Recognize ketoacidosis early
Pregnancy-associated DKA can occur at lower glucose levels than outside pregnancy. Type 1 diabetes care includes ketone-testing supplies and prevention education; concerning symptoms require urgent assessment even without marked hyperglycemia.
Plan postpartum care
Insulin requirements can fall sharply after delivery. People with gestational diabetes need a 75 g oral glucose tolerance test at 4 to 12 weeks postpartum and lifelong screening every one to three years.
Choose the postpartum test deliberately
At 4 to 12 weeks after GDM, OGTT is preferred to A1C because pregnancy-related red-cell turnover and delivery blood loss can lower A1C. Breastfeeding and irregular meals also warrant attention to insulin-associated hypoglycemia.
Quick check
Checking for saved practice…
Lesson
Hypertension, Preeclampsia, and Eclampsia
Hypertension after 20 weeks, proteinuria or end-organ findings, symptoms, fetal status, and severe-range pressure define the urgency of evaluation and treatment.
- Chronic hypertension
- Severe features
- Low-dose aspirin
- Magnesium
- Delivery planning
Match aspirin dose and timing to the guideline and risk profile
Proteinuria is not required when qualifying severe features are present
Treat severe pressure, use magnesium when indicated, and coordinate delivery
Recognize the syndrome
Preeclampsia can be diagnosed without proteinuria when new hypertension is accompanied by qualifying thrombocytopenia, renal insufficiency, liver dysfunction, pulmonary edema, persistent neurologic symptoms, or visual symptoms.
Prevent when eligible
ACOG recommends 81 mg aspirin daily for high-risk patients, started between 12 and 28 weeks, optimally before 16 weeks, and continued until delivery. It can be considered when more than one moderate-risk factor is present.
Identify the prevention population
High-risk histories include prior preeclampsia, chronic hypertension, pregestational diabetes, kidney disease, autoimmune disease, or multifetal gestation. Moderate-risk factors include first pregnancy, obesity, age at least 35, family history, and IVF conception. Assess combinations and contraindications; GDM alone is not equivalent to pregestational diabetes.
Name the guideline behind the aspirin dose
For preexisting type 1 or type 2 diabetes, ADA 2026 recommends 100 to 150 mg daily beginning at 12 to 16 weeks and allows 162 mg. This differs from ACOG/SMFM's 81 mg regimen. Verify the obstetric team's selected protocol and patient-specific risks; do not independently double a prescribed dose.
Treat chronic hypertension before severe range
ACOG's CHAP advisory uses 140/90 mm Hg as the threshold to initiate or titrate chronic-hypertension treatment in pregnancy. That threshold is not a universal target or an instruction to wait for severe hypertension. Labetalol and extended-release nifedipine are preferred maintenance options in the 2025 AHA/ACC guideline.
Distinguish the treatment goal from the threshold
SMFM recommends a goal below 140 systolic and below 90 diastolic for mild chronic hypertension in pregnancy. Continue effective pregnancy-compatible treatment or arrange a suitable replacement. This recommendation does not make 140/90 an exact desired reading, and CHAP did not establish that the lower targets used for nonpregnant adults should automatically be applied in pregnancy.
Respond promptly to lisinopril exposure
Lisinopril labeling calls for discontinuation as soon as pregnancy is detected. Contact the treating team promptly to arrange an appropriate replacement and continued blood-pressure management; do not wait for a later trimester or abnormal ultrasound. First-trimester observational evidence has important limitations and does not establish safety.
Check the whole renin-angiotensin regimen
The pregnancy warning also applies to ARBs such as losartan, the direct renin inhibitor aliskiren, and sacubitril/valsartan, which contains an ARB. Their labels call for prompt discontinuation when pregnancy is identified and consideration of alternative treatment. Changing from an ACE inhibitor to one of these is not a pregnancy-safety solution. A heart-failure indication requires coordinated cardiac and obstetric treatment planning.
Understand later fetal toxicity
Second- and third-trimester renin-angiotensin-system inhibition can impair fetal kidney function and reduce amniotic fluid, with pulmonary and skeletal complications or death. After exposure, coordinate obstetric assessment. Normal fluid on one scan does not exclude injury; oligohydramnios can emerge after damage. Exposed newborns may need observation for low blood pressure, reduced urine output, and hyperkalemia.
Distinguish atenolol from preferred pregnancy agents
Atenolol crosses the placenta, and its label reports an association between use beginning in the second trimester and small-for-gestational-age infants. Exposure around delivery can also cause neonatal bradycardia or hypoglycemia. Do not treat all beta blockers as interchangeable with labetalol. Review the maternal indication and arrange a supervised alternative and fetal/newborn monitoring plan; the exposure does not by itself prove a congenital malformation.
Treat the emergency
Systolic pressure at least 160 or diastolic pressure at least 110 mm Hg warrants prompt repeat measurement within 15 minutes. Confirmed severe hypertension requires treatment as soon as possible within 30 to 60 minutes, including postpartum. First-line options include IV labetalol, IV hydralazine, or immediate-release oral nifedipine; formulation and route matter. Magnesium sulfate is used to prevent or treat eclamptic seizures in indicated patients. Timing of delivery depends on severity, gestational age, maternal and fetal status, and response.
Use the acute nifedipine formulation
ACOG CO767's sample pathway starts immediate-release nifedipine 10 mg orally, reassesses blood pressure after 20 minutes, and uses 20 mg if severe pressure persists; another reassessment and 20 mg dose may follow after 20 minutes. Persistent severe pressure requires protocol-directed escalation and emergency consultation. Swallow capsules; do not puncture them or administer sublingually. Extended-release maintenance tablets are not an automatic substitute.
Keep IV dose intervals distinct
In CO767's sample pathways, labetalol progresses from 20 to 40 to 80 mg IV, with blood-pressure reassessment every 10 minutes before escalation. Hydralazine begins at 5 or 10 mg IV, with reassessment after 20 minutes and a further 10 mg if needed. These IV doses are administered over more than two minutes. Continued severe pressure requires the pathway's next agent and specialist escalation, not indefinite repetition.
Select around contraindications and monitor
Avoid labetalol in asthma or relevant bradycardia/cardiac disease; assess the specific contraindication and choose an appropriate alternative. Monitor maternal pressure, pulse and fetal status as applicable. With nifedipine plus magnesium, monitor for hypotension; magnesium does not replace urgent antihypertensive treatment.
Dose and monitor magnesium deliberately
The cited IV magnesium-sulfate label uses 4 to 6 g over 15 minutes, then 1 to 2 g/hour. Follow the obstetric protocol, verify concentration, and monitor respiration, reflexes, urine output, renal function, and magnesium. Myasthenia gravis is a contraindication.
Distinguish the obstetric regimen from the product label
ACOG Practice Bulletin 222 describes a 4 to 6 g IV loading dose over 20 to 30 minutes, then 1 to 2 g/hour. For indicated seizure prophylaxis, it describes continuing through cesarean delivery and for 24 hours afterward, or for 24 hours after vaginal delivery. These instructions differ from some product-label timing and cumulative-dose details. Document the selected obstetric protocol and reconcile it with the dispensed product and patient's renal function; a label comparison alone does not prove that a specialist-directed regimen is inappropriate.
Separate renal caution from contraindication
ACOG lists moderate-to-severe renal failure among magnesium contraindications, whereas the cited product label supplies severe-renal-impairment dosing instructions. Do not interpret that label schedule as automatic obstetric eligibility; obtain a specialist plan. For milder impairment (creatinine 1.0 to 1.5 mg/dL) or urine output below 30 mL/hour for more than four hours, ACOG describes 1 g/hour after loading and magnesium measurements every four hours. It advises stopping above 9.6 mg/dL, checking every two hours, and considering a lower-rate restart below 8.4 mg/dL. Clinical toxicity requires immediate action regardless of the laboratory schedule.
Respond to accumulation
Renal impairment needs dose adjustment and closer monitoring. The label limits severe-renal-impairment dosing to 20 g over 48 hours and advises stopping for urine output below 100 mL/4 hours, especially with rising creatinine. Significant toxicity requires stopping the infusion, urgent airway/ventilatory support as needed, and injectable calcium availability.
Make the toxicity response actionable
Absent reflexes with slowed breathing during magnesium infusion require immediate cessation, emergency help and respiratory support; do not wait for a laboratory result. AHRQ's example perinatal protocol uses calcium gluconate 1 g IV over five minutes for respiratory depression. A 10% solution contains 100 mg/mL, so 10 mL supplies 1 g of calcium gluconate, not 1 g of elemental calcium. Verify the product, order and institutional protocol. The antidote does not replace ventilation when needed.
Review cumulative exposure
The cited magnesium product limits total dosing to 30 to 40 g over 24 hours, with the lower severe-renal-impairment limit described above. A maintenance rate cannot be continued indefinitely without reassessing the total dose and clinical status. Administration beyond five to seven days is not recommended because fetal hypocalcemia and skeletal injury can occur; this warning is not a recommended treatment duration.
Check the rate against the planned duration
In a fictional order, a 4 g loading dose plus a full 24 hours of maintenance at 2 g/hour delivers 52 g in total. The maintenance alone delivers 48 g in 24 hours, exceeding the cited product's 30 to 40 g per 24-hour maximum. An hourly rate within the listed range does not validate the whole order: clarify the intended loading and maintenance timeline, cumulative limit, renal adjustment and obstetric protocol before administration. This arithmetic example identifies a label discrepancy, not proof of toxicity or a reason to interrupt indicated seizure prophylaxis without a coordinated plan.
Check the pump calculation
For an illustrative prescribed infusion of 2 g/hour from a bag labeled 20 g/500 mL: concentration is 0.04 g/mL, so 2 divided by 0.04 equals 50 mL/hour. Verify the actual bag, order, fluid allowance, and pump settings; bag concentration does not determine the clinical dose.
Quick check
Checking for saved practice…
Lesson
Venous Thromboembolism and Peripartum Anticoagulation
Pregnancy and the postpartum period increase thrombosis risk while delivery and neuraxial procedures make anticoagulant timing a high-stakes coordination problem.
- VTE risk
- LMWH
- UFH
- Warfarin
- Neuraxial planning
Match prevention or treatment intensity to risk and organ function
Verify the exact dose-specific interruption interval and reversal options
Balance bleeding, thrombosis, breastfeeding, duration, and follow-up
Assess the event and risk
Symptoms suggesting deep-vein thrombosis or pulmonary embolism need urgent diagnostic evaluation. Previous VTE, thrombophilia, cesarean delivery, immobilization, obesity, and postpartum status change prophylaxis decisions.
Choose pregnancy-compatible therapy
Low-molecular-weight heparin is commonly preferred for treatment during pregnancy because it does not cross the placenta. Unfractionated heparin can be useful when rapid offset or reversal is important. Warfarin is generally avoided during pregnancy but can be compatible with breastfeeding.
Avoid a universal anti-Xa rule
For therapeutic LMWH used to treat pregnancy-associated VTE, ASH conditionally recommends against routine anti-Xa-guided dose adjustment, with low-certainty evidence. This recommendation did not address extremes of body weight or renal dysfunction. It also does not replace the different monitoring requirements of a mechanical-valve regimen.
Separate mechanical-valve anticoagulation
A mechanical valve requires a specialist maternal-cardiology plan because valve thrombosis can be catastrophic. Warfarin may remain part of an individualized pregnancy regimen despite fetal risks; it is not interchangeable with a routine VTE pathway. If LMWH is selected, dose-adjusted treatment and anti-Xa monitoring are essential. ACC/AHA describes a peak target of 0.8 to 1.2 U/mL at four to six hours after dosing. Do not substitute a direct oral anticoagulant or stop anticoagulation without a coordinated transition.
Individualize valve monitoring
ESC 2025 recommends a Pregnancy Heart Team and advises against LMWH for mechanical valves when anti-Xa monitoring is unavailable. Its narrative individualizes peak targets between 1.0 and 1.2 IU/mL, while its dosing table lists 0.8 to 1.2 U/mL; specify the specialist-selected target rather than silently merging these ranges. Check levels at least weekly until on target or after a below-target result, then typically every two to four weeks when stable. Low-dose warfarin still carries fetal risk; agent selection requires shared maternal-fetal risk assessment.
Select postpartum therapy for the feeding plan
UFH, LMWH, and warfarin are established breastfeeding-compatible options. ASH's 2018 guideline recommends against DOACs during breastfeeding, based on very-low-certainty evidence; its pregnancy guideline update is in development. More recent evidence is drug specific: LactMed's August 2026 rivaroxaban review describes low milk exposure and states that required maternal therapy does not itself require stopping breastfeeding. This does not establish universal first-line use or safety for every infant. Review the indication, infant maturity and health, alternatives, and bleeding surveillance with the treating team.
Do not generalize rivaroxaban findings to apixaban
LactMed's May 2026 apixaban review reports relatively high milk transfer and prefers an alternative, particularly for newborn or premature infants. Published infant clinical-outcome information remains lacking; predicted anticoagulation risk is not proof of an observed bleeding event. Explain the difference between measured milk concentrations, modeled exposure, and observed infant outcomes. Never interrupt needed maternal anticoagulation while resolving a feeding or drug-selection question.
Meet both VTE treatment-duration requirements
For confirmed pregnancy-associated DVT or PE, RCOG recommends therapeutic anticoagulation through the remainder of pregnancy, for at least six weeks after birth, and until at least three months of treatment have been completed overall. These are concurrent minimum requirements, not alternative stop dates. A clot diagnosed close to delivery may require treatment beyond six weeks postpartum to complete the total course. Reassess ongoing thrombosis and bleeding risks before stopping; a separate long-term indication may require longer treatment. This treatment rule is not a universal prophylaxis duration.
Distinguish neuraxial placement from restart
ASRA 2025 recommends waiting at least 12 hours after low-dose LMWH, such as enoxaparin 40 mg daily or 30 mg twice daily, before neuraxial needle placement. High-dose treatment, such as enoxaparin 1 mg/kg twice daily, requires at least 24 hours. These minimums do not guarantee safety when clearance is impaired or other bleeding risks are present. Confirm the actual regimen and anesthesia plan.
Apply all relevant restart intervals
For twice-daily low-dose LMWH, ASRA places the first postoperative dose the following day and at least 12 hours after placement; remove the catheter first and wait at least four hours after removal. With once-daily low-dose LMWH, start at least 12 hours after placement; the second dose is at least 24 hours later. Remove the catheter at least 12 hours after the last dose and wait four hours before redosing. High-dose restart requires at least 24 hours after placement and four hours after removal, plus the surgical interval: 24 hours for non-high bleeding risk or 48 to 72 hours for high bleeding risk. Hemostasis and individualized obstetric planning remain necessary.
Coordinate the peripartum plan
Neuraxial and delivery timing depends on drug, dose, renal function, last administration, bleeding risk, and local anesthesia protocol. Exact intervals are regimen specific and should be verified rather than memorized as one universal rule.
Quick check
Checking for saved practice…
Lesson
Lactation Exposure Science
Infant exposure through milk depends on maternal concentration, milk transfer, oral absorption, dose timing, milk intake, infant clearance, and the medicine's active metabolites.
- Milk to plasma ratio
- Relative infant dose
- Oral bioavailability
- Infant age
- Milk production
Binding, ionization, lipid solubility, transport, and time affect concentration
RID compares ingested doses; oral absorption and toxicity require separate assessment
Prematurity, illness, and neonatal age can increase accumulation
Trace the exposure
Many drugs enter milk by passive diffusion. Lipophilicity, ionization, protein binding, molecular size, active transport, milk composition, maternal dose, and time since dose influence milk concentration.
Calculate relative infant dose
Relative infant dose compares the estimated infant dose in milk, normalized to infant weight, with the maternal weight-normalized dose. A lower value can be reassuring, but potency, toxicity, metabolites, and vulnerable infants still matter.
Work through an exposure estimate
For a fictional drug, assume average milk concentration 2 mg/L, milk intake 150 mL/kg/day (0.15 L/kg/day), maternal dose 300 mg/day and maternal weight 60 kg. Infant ingestion is 2 times 0.15 = 0.30 mg/kg/day. Maternal weight-adjusted dose is 300/60 = 5 mg/kg/day. RID is (0.30/5) times 100 = 6 percent. Use a representative average concentration, not a random peak, and state all assumptions.
Interpret the calculation
The 150 mL/kg/day milk volume is a standard estimation assumption, not a feeding prescription. At half that milk intake with unchanged concentration, estimated drug ingestion and RID halve. RID describes an ingested dose comparison, not infant blood concentration or probability of harm. Check active metabolites, oral absorption, infant clearance and drug-specific toxicity before recommending a feeding plan.
Account for the infant
Prematurity, neonatal age, illness, feeding volume, and immature renal or hepatic clearance can increase risk. Also assess whether a medicine reduces milk production or whether avoiding treatment threatens maternal health or feeding goals.
Quick check
Checking for saved practice…
Lesson
Nutrition During Breastfeeding
Maternal intake and infant supplementation are separate decisions that depend on age, feeding pattern, growth and the exact supplement formulation.
- Maternal energy
- Iodine and choline
- Infant vitamin D
- Elemental iron
- Concentration checks
Assess energy, iodine and choline against total intake
Plan vitamin D and iron with term status and growth in view
Check elemental iron and IU per drop versus IU per mL
Support a sustainable feeding plan
AAP recommends exclusive breastfeeding for about six months, then appropriate complementary foods with continued breastfeeding through two years or longer when mutually desired. Six months marks complementary-food introduction, not an automatic stopping date. Discuss family goals without pressure, assess infant growth and intake, and arrange feeding support or suitable alternatives when needed.
Individualize maternal intake
CDC recommends about 330 to 400 additional kcal/day above pre-pregnancy intake for well-nourished breastfeeding mothers, adjusted for activity, body size and feeding pattern. Lactation targets include total iodine 290 mcg/day and choline 550 mg/day. Review food intake and supplement contents rather than assuming every prenatal product meets those needs.
Provide infant vitamin D
Breast milk alone does not supply sufficient vitamin D. Give 400 IU/day beginning in the first days of life for breastfed infants; CDC also specifies supplementation for partly breastfed infants taking less than 32 ounces of formula daily. Confirm formula intake and its vitamin D contribution with the pediatric plan. Routine maternal supplementation does not automatically replace the infant dose.
Plan infant iron by risk
For a healthy term breastfed infant, AAP recommends oral iron 1 mg/kg/day from four months until appropriate iron-containing complementary foods meet the need. Prematurity, low birth weight and other risk factors require an earlier individualized plan. Do not stop automatically at six months merely because solids have been offered.
Calculate from the label
For an illustrative prescribed elemental-iron dose of 1 mg/kg/day in a 6 kg infant, the dose is 6 mg/day. If the product contains 15 mg elemental iron per mL, administer 6/15 = 0.4 mL/day. Vitamin D products may state IU per drop or per mL: these are different concentrations. Verify the label and measuring device every time a product changes; keep supplements out of children's reach.
Quick check
Checking for saved practice…
Lesson
Medication Selection During Lactation
Good lactation care treats maternal disease while minimizing infant harm through drug-specific evidence, dose design, infant monitoring, and feeding support.
- LactMed
- FDA section 8.2
- Infant monitoring
- Codeine
- Shared decision
Avoid fixed class lists and use the exact product, dose, and duration
Choose a suitable drug and formulation without relying on universal feed timing
Name observable signs, maternal goals, follow-up, and an escalation route
Distinguish low-dose methotrexate guidance
The U.S. tablet label advises no breastfeeding during treatment and for one week after the final dose. EULAR 2024 allows considering methotrexate up to 25 mg weekly only when no breastfeeding-compatible alternative can be used, based on limited evidence. This is a specialist exception, not a statement that high-dose cancer regimens are compatible. Document the selected guidance and infant follow-up plan.
Separate contrast agents from radiopharmaceuticals
ACR 2026 supports continued breastfeeding after intravascular iodinated or gadolinium-based contrast; routine 24-hour interruption is unnecessary. Milk transfer and infant gut absorption are small, although evidence is limited. Explain the evidence and respect an informed preference for temporary interruption. These agents are not radioactive iodine, and lactation compatibility does not establish pregnancy compatibility.
Plan therapeutic radioiodine before treatment
Sodium iodide I-131 is contraindicated during lactation. Its cited therapeutic label requires stopping breastfeeding and pumping at least six weeks before administration; current LactMed describes six to twelve weeks before treatment. Coordinate the interval with nuclear medicine. After therapeutic I-131, breastfeeding must not resume for the current child. Radiation-contact restrictions are separate from milk-feeding restrictions and require an individualized written plan.
Identify the diagnostic radionuclide
Diagnostic sodium iodide I-123 uses a temporary interruption rather than the permanent cessation required after therapeutic I-131. LactMed reports a three-to-four-day interval from U.S. recommendations, with other protocols differing by activity and product purity. Nuclear medicine should specify the exact agent, administered activity, milk handling, restart time and whether milk radioactivity measurement is needed. Do not assign a universal interval to every scan.
Use drug-specific evidence
Consult NIH LactMed, current FDA labeling, specialist guidelines, and primary evidence. Broad class avoid lists become outdated and can cause unnecessary interruption of breastfeeding or undertreatment of the lactating patient.
Choose compatible postpartum analgesia
Acetaminophen and ibuprofen are useful first choices during breastfeeding when appropriate for the parent. Milk exposure is low; lactation compatibility does not remove the need to check maternal contraindications, other products containing the same ingredient, and the prescribed dose. Persistent or worsening pain requires reassessment rather than automatic escalation to a sedating medicine.
Distinguish prescribed stimulant treatment
LactMed describes expert support for therapeutic amphetamine use with infant monitoring, despite more restrictive manufacturer advice. Assess the exact product, dose, infant feeding, sleep, irritability, growth and maternal milk supply; long-term infant neurodevelopmental evidence is limited. Do not equate a supervised ADHD regimen with ongoing nonprescribed stimulant use. Document the chosen guidance with the prescriber and pediatric team.
Monitor phenobarbital exposure
Phenobarbital milk transfer varies considerably, especially with interacting antiseizure medicines. Monitor infant alertness, feeding and weight gain; excessive drowsiness or poor growth can require a change in feeding or treatment. An infant serum concentration can help assess suspected toxicity. Coordinate changes with neurology and pediatrics to preserve maternal seizure control.
Separate statin pregnancy and feeding advice
FDA removal of the universal pregnancy contraindication did not endorse breastfeeding during statin treatment. Discuss whether cardiovascular risk permits a temporary statin interruption. If ongoing treatment is necessary, FDA advises an alternative feeding source. Do not discontinue essential cardiovascular prevention solely to maintain breastfeeding without a shared clinical plan.
Avoid unsafe shortcuts
FDA recommends against codeine and tramadol during breastfeeding because variable metabolism can expose an infant to serious opioid toxicity. Timing doses after feeds cannot reliably neutralize every long half-life, active metabolite, sustained-release, or high-risk medicine.
Distinguish metronidazole regimens
Do not treat metronidazole as a universal reason to stop breastfeeding. LactMed describes differing expert advice, especially for prolonged therapy. Some sources advise a 12 to 24 hour interruption after a single 2 g dose, but not after lower doses. Review the exact route and product label because vaginal-product instructions can differ. Monitor for infant diarrhea or thrush and reconcile any interruption with the clinical team.
Avoid breastfeeding during thalidomide or lenalidomide
Both product labels advise against breastfeeding during treatment because serious infant adverse effects are possible and human milk data are lacking. Arrange an alternative feeding plan with the oncology and pediatric teams; absence of measured milk concentrations does not establish compatibility.
Apply the nasal dihydroergotamine feeding interval
TRUDHESA labeling advises no breastfeeding during treatment and for three days after the last dose; express and discard milk during that interval and arrange another infant-feeding source. The concern includes reduced milk supply and serious infant cardiovascular or gastrointestinal effects. This is a product-specific instruction, not an interval to apply automatically to every ergot or migraine medicine.
Use drug-specific antiarrhythmic feeding advice
MULTAQ labeling advises no breastfeeding during treatment or for five days after the last dose because of potential serious infant harm and absent human milk data. Amiodarone labeling also advises against breastfeeding during treatment; drug and metabolite enter milk, with concern for infant thyroid and cardiac effects. Do not transfer dronedarone's five-day interval to amiodarone. Arrange a coordinated cardiology, pediatric and feeding plan when continued treatment is necessary.
Treat lithium as a monitored specialist decision
Lithium transfer and infant serum concentrations vary substantially. LactMed does not regard it as absolutely contraindicated for every healthy full-term infant, especially beyond two months with maternal monotherapy. This is not unrestricted compatibility: prematurity, neonatal age, dehydration and impaired elimination increase concern. A coordinated psychiatric and pediatric plan must address maternal control, infant feeding and hydration, clinical observations and appropriate lithium, renal and thyroid laboratory monitoring. Do not substitute feed timing for that plan.
Discuss HIV feeding options
Properly prepared formula or banked pasteurized donor milk eliminates HIV transmission through breast milk. With consistent ART and HIV RNA below 50 copies/mL for at least three months before delivery, current NIH guidance supports counseling about these options and breastfeeding. Sustained suppression lowers breastfeeding transmission risk below 1%, but does not eliminate it. Arrange specialist follow-up, parental viral-load monitoring and infant testing/prophylaxis.
Respond to detectable HIV RNA
During breastfeeding, HIV RNA at least 50 copies/mL requires temporary interruption or discontinuation and replacement feeding while the team reassesses. Most experts recommend permanent cessation at 200 copies/mL or higher. Continuing care and support remains essential.
Account for atenolol exposure through milk
Atenolol labeling warns of bradycardia and hypoglycemia in infants exposed through breastfeeding. Assess the exact maternal regimen, infant health, feeding and symptoms with the care team. Poor feeding, unusual lethargy or an abnormally slow pulse warrants prompt assessment rather than reassurance based only on the beta-blocker class. Lomitapide labeling advises against breastfeeding during treatment.
Monitor what matters
Define infant signs such as sedation, poor feeding, respiratory depression, diarrhea, rash, jaundice, irritability, or inadequate weight gain according to the drug. Include maternal response, milk supply, duration, and an escalation plan.
Quick check
Checking for saved practice…
Module practice
Check the connections.
Each attempt draws 10 questions from the complete 130 question bank.
Each attempt draws a fresh set and rearranges the answer choices.
References
Current clinical foundation.
Core source material was synthesized with the following contemporary guidance. Verify local policy and current guidance before applying clinical information.
- SMFM: CHAP implementation statement, reaffirmed 2024
- ACOG Practice Bulletin 222 (2020), magnesium regimen and peripartum continuation; Kansas Perinatal Quality Collaborative hosted copy.
- FDA. PLLR questions and answers: older prescriptions, OTC scope and reproductive potential.
- DailyMed. Cimzia: pregnancy data and antibody structure, sections 8.1 and 12.1.
- DailyMed. Remicade: placental transfer and infant exposure, section 8.1.
- MONEAD antiseizure dosing in pregnancy and early postpartum (2026)
- MONEAD dosing analysis correction (July 2026)
- ESC 2025 cardiovascular disease and pregnancy guideline, sections 5.2.1 and 12.5.3: mechanical valves.
- ASRA 2025 fifth edition: LMWH and neuraxial procedures.
- RCOG Green-top Guideline 37b (2015), current linked acute-VTE guideline: treatment duration and delivery planning.
- CDC. 2026-2027 COVID-19 clinical guidance, September 23, 2026.
- CDC. COVID-19 guidance for immunocompromised people, September 23, 2026.
- LactMed glossary. Weight-adjusted dose and relative infant dosage.
- DailyMed. Tramadol tablets, section 8.2: lactation and infant monitoring.
- RCOG Green-top Guideline 69 (2024). Hyperemesis assessment and treatment.
- RCOG Guideline 69 correction (2025). Fluid terminology and UK prochlorperazine route.
- RCOG Guideline 69 correction (2026). Appendix Vb potassium infusion duration.
- UK WindSetlers SmPC. Simethicone pharmacokinetics and pregnancy precautions.
- LactMed. Simethicone, February 15, 2026.
- UK Gaviscon Double Action Mint chewable SmPC. Pregnancy and formulation precautions.
- UK Maalox Plus suspension SmPC. Pregnancy and interaction assessment.
- MONEAD primary cohort study. Antiseizure medication concentrations during pregnancy, JAMA Neurology 2022.
- WHO. Ferritin guideline 2020: pregnancy thresholds and inflammation context.
- DailyMed. Delsym extended-release suspension, Drug Facts, revised September 2026.
- MotherToBaby. Dextromethorphan, July 1, 2026.
- MotherToBaby. Guaifenesin, December 1, 2024.
- CDC U.S. MEC 2024. Combined hormonal contraception: inadvertent pregnancy exposure.
- AAP. Breastfeeding duration, complementary foods and family support.
- LactMed. Amphetamine, June 15, 2025.
- LactMed. Phenobarbital, September 15, 2024.
- LactMed. Ibuprofen, August 15, 2025.
- LactMed. Acetaminophen, April 15, 2026.
- ACR Manual on Contrast Media 2026, breastfeeding chapter (2024 evidence update).
- LactMed. Sodium iodide I-123, June 15, 2026.
- LactMed. Sodium iodide I-131, September 15, 2026.
- DailyMed. Therapeutic sodium iodide I-131, lactation precautions.
- NIH. HIV-associated Pneumocystis pneumonia: pregnancy treatment, prophylaxis and folate.
- DailyMed. Vibativ: embryo-fetal toxicity and reproductive precautions.
- Joint Commission 2026B: Previous births and parity definitions
- OpenStax: First prenatal visit, gravidity and parity
- RCOG: Ectopic pregnancy and pregnancy of unknown location
- MotherToBaby: Critical periods of development
- NICHD: About pregnancy and term definitions
- DailyMed: Megestrol acetate oral suspension reproductive precautions
- DailyMed: Testosterone gel 1.62% secondary exposure and pregnancy
- Pfizer: Duavee prescribing information
- Lilly: Evista prescribing information
- DailyMed: Atenolol pregnancy and nursing precautions
- DailyMed: JUXTAPID reproductive precautions
- DailyMed: Tegretol pregnancy warning
- DailyMed: Phenytoin pregnancy dosing and fetal risk
- Qsymia prescribing information, March 2026
- Wegovy prescribing information
- Zepbound prescribing information, August 2026
- FDA: ERA REMS changes and continuing pregnancy precautions
- TRACLEER prescribing information
- DailyMed: Ambrisentan prescribing information
- WHO 2025: Sickle-cell disease during pregnancy, recommendation 1f
- DailyMed: SIKLOS prescribing information
- DailyMed: HYDREA prescribing information
- BMS: THALOMID prescribing information
- BMS: REVLIMID prescribing information
- DailyMed: Ribavirin capsules, Aurobindo reproductive precautions
- DailyMed: Ribavirin tablets reproductive precautions
- AASLD/IDSA: HCV in pregnancy
- DailyMed: Cytotec prescribing information
- WHO: Abortion care guideline, second edition executive summary
- DailyMed: TRUDHESA, revised May 2026
- DailyMed: Cafergot pregnancy precautions
- DailyMed: Gentamicin injection warnings
- UKTIS: Aminoglycoside antibiotics in pregnancy, public summary
- CDC: Tuberculosis treatment during pregnancy
- DailyMed: Fluconazole fetal-harm warning
- DailyMed: Voriconazole reproductive labeling
- DailyMed: Griseofulvin microsize reproductive precautions
- Sanofi: MULTAQ prescribing information, revised May 2025
- DailyMed: Amiodarone tablets, pregnancy and lactation
- ACC: 2023 HRS arrhythmias during pregnancy guidance
- DailyMed: Lithium carbonate capsules, pregnancy dosing and pharmacokinetics
- FDA: Benzodiazepine dependence and withdrawal safety
- ACOG Clinical Practice Guideline 5: Perinatal Mental Health
- DailyMed: Paroxetine reproductive risks
- DailyMed: Finasteride pregnancy and handling
- DailyMed: Dutasteride pregnancy and handling
- DailyMed: Leflunomide accelerated elimination and pregnancy
- DailyMed: Methotrexate tablets reproductive labeling
- EULAR reproductive recommendations: 2024 update
- DailyMed: Losartan pregnancy labeling
- DailyMed: Aliskiren pregnancy labeling
- DailyMed: Entresto pregnancy labeling
- DailyMed: Lisinopril, fetal toxicity and pregnancy
- CDC: guidelines for vaccinating pregnant women.
- AAN/AES/SMFM: 2024 pregnancy antiseizure guideline summary.
- DailyMed: Valproic acid pregnancy precautions.
- FDA: Current iPLEDGE implementation status.
- DailyMed: Isotretinoin pregnancy and prevention labeling.
- MotherToBaby: Topical tretinoin exposure.
- WHO: 2024 hemoglobin diagnostic thresholds.
- FIGO: 2025 anemia in pregnancy recommendations.
- GINA: 2026 asthma summary guide, pregnancy and follow-up.
- NHS SPS: Allergic rhinitis during pregnancy.
- ACAAI: Managing allergies during pregnancy.
- ACOG: Allergy medicines during pregnancy.
- NHS: Heartburn during pregnancy.
- UKTIS BUMPS: Constipation treatment and laxatives, March 2026.
- CDC: COVID-19 vaccination during pregnancy and breastfeeding.
- ACOG: March 2026 COVID-19 vaccination recommendation.
- CDC: Rabies post-exposure prophylaxis.
- CDC: Infant RSV immunization guidance.
- CDC: Tdap vaccination during pregnancy.
- CDC: RSV vaccine guidance for pregnant women.
- CDC: folic acid facts for clinicians, July 2026.
- CDC: clinical care of Rocky Mountain spotted fever, pregnancy treatment.
- Cipro prescribing information: pregnancy evidence and limitations.
- Endometrin: progesterone vaginal insert prescribing information, July 2026.
- NICE NG126: management of miscarriage, progesterone recommendations.
- FDA: statin pregnancy contraindication removal and ongoing precautions, July 2021.
- CDC alcohol and pregnancy, reviewed August 2026.
- USPSTF 2021 tobacco cessation: pregnant-person behavioral treatment and pharmacotherapy evidence.
- CDC e-cigarettes and pregnancy.
- CDC cannabis and pregnancy (2025).
- CDC opioid use disorder treatment during and after pregnancy (May 2026).
- RCOG Green-top Guideline 68 (2016), section 6.8: maternal vitamin K evidence and neonatal prophylaxis.
- AAP (May 2026): Vitamin K Helps Prevent Dangerous Bleeding Disorders in Newborns.
- AHRQ Safe Medication Administration: Magnesium Sulfate. Perinatal safety and example toxicity response (reviewed July 2023).
- Magnesium sulfate in dextrose: prescribing information, revised June 2026.
- USPSTF: aspirin for preeclampsia prevention, 2021.
- ACOG: CHAP study integration, 2022.
- ACOG Committee Opinion 767: acute severe hypertension.
- AHA/ACC hypertension guideline, 2025: pregnancy recommendations.
- LactMed: rivaroxaban, revised August 15, 2026.
- LactMed: apixaban, revised May 15, 2026.
- ASH pregnancy VTE guideline and update status.
- ASH pregnancy VTE guideline: recommendation 5 and monitoring scope.
- ACC/AHA 2020 valve guideline: pregnancy and mechanical-valve anticoagulation summary.
- CDC. Maternal diet and breastfeeding, August 25, 2026.
- CDC. Vitamin D and breastfeeding, July 21, 2026.
- AAP HealthyChildren. Vitamin D and iron supplements for babies.
- LactMed. Metronidazole, revised March 15, 2026.
- LactMed. Lithium, revised June 15, 2026.
- NIH LactMed. Record format and relative infant dose methodology.
- ATA 2026 pregnancy and postpartum thyroid guideline: replacement and antithyroid treatment.
- ATA. Hypothyroidism in pregnancy: administration and monitoring.
- Macrobid prescribing information: formulation-specific dose and administration.
- Fosfomycin tromethamine prescribing information: single-dose cystitis treatment and preparation.
- ACOG Committee Opinion 797 (2020): GBS bacteriuria and intrapartum prophylaxis.
- ACOG. Urinary tract infections in pregnant individuals, 2023.
- DailyMed. Macrobid contraindications.
- CDC. Vulvovaginal candidiasis: pregnancy.
- CDC. Preventing toxoplasmosis.
- CDC. Toxoplasmosis risk and pregnancy precautions.
- ACOG. Acetaminophen use in pregnancy and neurodevelopmental outcomes, September 2025.
- FDA. Acetaminophen pregnancy safety communication, September 22, 2025.
- FDA. Acetaminophen safe use and pregnancy information.
- DailyMed. Diclegis prescribing information, sections 1 to 5.
- DailyMed. Bonjesta prescribing information, sections 1 to 5.
- FDA. NSAID pregnancy renal and amniotic-fluid warning.
- NIH ODS. Dietary Supplements and Life Stages: Pregnancy; nutrient targets and folate units.
- FDA. Reformulated ranitidine approval, November 24, 2025.
- NIH. Preventing HIV transmission during infant feeding, June 25, 2026.
- FDA Pregnancy and Lactation Labeling Resources
- NIH Drugs and Lactation Database, LactMed
- ADA Standards of Care 2026: Management of Diabetes in Pregnancy
- ACOG: Low-Dose Aspirin Use During Pregnancy
- ACOG: Morning Sickness, Nausea and Vomiting of Pregnancy
- ACOG Practice Bulletin: Thromboembolism in Pregnancy, Reaffirmed 2025
- FDA Codeine and Tramadol Breastfeeding Safety Information